Related references
Note: Only part of the references are listed.Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Allison Betof Warner et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies
Phyllis Butow et al.
JOURNAL OF CANCER SURVIVORSHIP (2020)
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy (vol 28, pg 2707, 2017)
C. E. McCoach et al.
ANNALS OF ONCOLOGY (2019)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L. Tan et al.
ANNALS OF ONCOLOGY (2019)
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y. J. L. Jansen et al.
ANNALS OF ONCOLOGY (2019)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Celeste Lebbe et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
Padmanee Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy
Henry T. Quach et al.
ONCOLOGIST (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1175ODurvalumab activity in previously treated patients who stopped durvalumab without disease progression
S Sheth et al.
ANNALS OF ONCOLOGY (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
A meta-review of qualitative research on adult cancer survivors: current strengths and evidence gaps
Rebekah Laidsaar-Powell et al.
JOURNAL OF CANCER SURVIVORSHIP (2019)
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Marie-Lea Gauci et al.
CLINICAL CANCER RESEARCH (2019)
Imaging of Cancer Immunotherapy: Current Approaches and Future Directions
Mizuki Nishino et al.
RADIOLOGY (2019)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018
F. Stiefel et al.
ANNALS OF ONCOLOGY (2018)
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
A. C. Tan et al.
ANNALS OF ONCOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Is earlier better for melanoma checkpoint blockade?
Caroline Robert
NATURE MEDICINE (2018)
Immune checkpoint inhibitors-related orchitis
F. Brunet-Possenti et al.
ANNALS OF ONCOLOGY (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Anxiety and Depression in Cancer Survivors
Jean C. Yi et al.
MEDICAL CLINICS OF NORTH AMERICA (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
Luc Cabel et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2017)
Communication about uncertainty and hope: A randomized controlled trial assessing the efficacy of a communication skills training program for physicians caring for cancer patients
Yves Libert et al.
BMC CANCER (2017)
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol et al.
CANCER TREATMENT REVIEWS (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer
Julie N. Graff et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
Caroline Robert et al.
CLINICAL CANCER RESEARCH (2013)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
Distress Management Clinical Practice Guidelines in Oncology
Jimmie C. Holland et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians
John D. Mathews et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Use of the Word Cure in Oncology
Kenneth Miller et al.
JOURNAL OF ONCOLOGY PRACTICE (2013)
Impact of whole body Magnetic Resonance Imaging (MRI) in the management of melanoma patients, in comparison with positron emission tomography/computed tomography (TEP/CT) and CT
P. Dellestable et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2011)
PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT
Thomas Pfluger et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hope in the Context of Lung Cancer: Relationships of Hope to Symptoms and Psychological Distress
David Berendes et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Axel Hoos et al.
SEMINARS IN ONCOLOGY (2010)
Share Paper
